These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3533884)

  • 41. Prulifloxacin. NAD-441A, NM 441, Quisnon.
    Drugs R D; 2002; 3(6):426-30. PubMed ID: 12516950
    [No Abstract]   [Full Text] [Related]  

  • 42. The John Barnwell Lecture. The chemotherapy of bacterial respiratory infections.
    Crofton J
    Am Rev Respir Dis; 1970 Jun; 101(6):841-59. PubMed ID: 4914352
    [No Abstract]   [Full Text] [Related]  

  • 43. Moxifloxacin for bacterial keratitis.
    Rosenberg J; Eisen L; Kim J
    Ophthalmology; 2008 Jun; 115(6):1103; author reply 1103. PubMed ID: 18519075
    [No Abstract]   [Full Text] [Related]  

  • 44. In vitro development of resistance to three quinolones in Streptococcus pneumoniae.
    Rodríguez JC; Llinares F; Royo G
    Chemotherapy; 2001; 47(1):39-42. PubMed ID: 11125231
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical efficacy of the new quinolones in lower respiratory infections.
    Davies BI; Maesen FP
    Chemioterapia; 1987 Jun; 6(2 Suppl):447-8. PubMed ID: 3509469
    [No Abstract]   [Full Text] [Related]  

  • 46. New and future antibiotics in the treatment of acute respiratory tract infections.
    Wise R
    Thorax; 1995 Mar; 50(3):223-4. PubMed ID: 7660331
    [No Abstract]   [Full Text] [Related]  

  • 47. [Trovafloxacin].
    Azanza JR; Ollero D; Sádaba B; García Quetglas E
    Rev Med Univ Navarra; 1999; 43(1):45-57. PubMed ID: 10386346
    [No Abstract]   [Full Text] [Related]  

  • 48. Respiratory fluoroquinolones: differences in the details.
    Mandell LA; Iannini PB; Tillotson GS
    Clin Infect Dis; 2004 May; 38(9):1331-2; author reply 1332-3. PubMed ID: 15127351
    [No Abstract]   [Full Text] [Related]  

  • 49. [Levofloxacin in the treatment of respiratory infections].
    Iakovlev SV; Iakovlev VP
    Antibiot Khimioter; 2002; 47(8):32-42. PubMed ID: 12515095
    [No Abstract]   [Full Text] [Related]  

  • 50. A single blind clinical study comparing trimethoprim with co-trimoxazole in acute chest infections in the elderly.
    Gonsalkorale M
    Br J Clin Pract; 1987 May; 41(5):743-6. PubMed ID: 3502250
    [No Abstract]   [Full Text] [Related]  

  • 51. [Recent fluoroquinolones. Highly effective weapons for ambulatory therapy].
    Stahlmann R; Lode H
    MMW Fortschr Med; 1999 Nov; 141(47):35-6. PubMed ID: 10912165
    [No Abstract]   [Full Text] [Related]  

  • 52. [Evaluation of the clinical efficacy and safety of injectable quinolones in the treatment of respiratory tract infections (discussion)].
    Kohno S; Watanabe A; Mikasa K; Asano K
    Jpn J Antibiot; 2003 Apr; 56(2):93-104. PubMed ID: 12825412
    [No Abstract]   [Full Text] [Related]  

  • 53. Antibiotic resistance in gonorrhoea with special reference to rosoxacin in the treatment of a multi-resistant case.
    Mahendran R; Jayakuru GN
    Ceylon Med J; 1981 Jun; 26(2):94-8. PubMed ID: 6821032
    [No Abstract]   [Full Text] [Related]  

  • 54. Drug Points: tachycardia associated with moxifloxacin.
    Siepmann M; Kirch W
    BMJ; 2001 Jan; 322(7277):23. PubMed ID: 11141146
    [No Abstract]   [Full Text] [Related]  

  • 55. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.
    Balfour JA; Lamb HM
    Drugs; 2000 Jan; 59(1):115-39. PubMed ID: 10718103
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ofloxacin in lower respiratory tract infections.
    Hänninen P
    Drugs; 1987; 34 Suppl 1():179-80. PubMed ID: 3481320
    [No Abstract]   [Full Text] [Related]  

  • 57. Evaluation of the clinical microbiology profile of moxifloxacin.
    Krasemann C; Meyer J; Tillotson G
    Clin Infect Dis; 2001 Mar; 32 Suppl 1():S51-63. PubMed ID: 11249830
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Choosing the ideal antibiotic therapy and the role of the newer fluoroquinolones in respiratory tract infections.
    Owens RC
    Am J Manag Care; 2000 May; 6(8 Suppl):S442-7. PubMed ID: 10977484
    [No Abstract]   [Full Text] [Related]  

  • 59. Respiratory tract committee, protocol composition committee, clinical trial committee, Japanese society of chemotherapy.
    Saito A; Aoki N; Odagiri S; Niki Y; Yamaguchi K; Utada N; Kaneko I; Sasaki K; Sasaki M; Maruo A
    J Infect Chemother; 2002 Sep; 8(3):273-319. PubMed ID: 12373495
    [No Abstract]   [Full Text] [Related]  

  • 60. Efficacy and tolerability of moxifloxacin in patients with respiratory tract infections treated in general practice: Results of a post-marketing surveillance study.
    Chen W; Wu C; Li Z; Bai C
    Clin Drug Investig; 2006; 26(9):501-9. PubMed ID: 17163283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.